Open AccessSiltuximab - A monoclonal antibody against the interleukin-6 receptor is not an ideal option for management of COVID-19
Author(s) -
I Jerlin Michelle,
S. A. Shevaani,
Kiran Kumar Rathinam,
Justin Jacob Abraham,
Muhasaparur Ganesan Rajanandh,
Thangavel Mahalingam Vijayakumar
Publication year - 2021
Publication title -
current medicine research and practice
Language(s) - English
Resource type - Journals
eISSN - 2352-0825
pISSN - 2352-0817
DOI - 10.4103/cmrp.cmrp_28_20
Subject(s) - cytokine storm , monoclonal antibody , covid-19 , coronavirus , immunology , medicine , pandemic , cytokine release syndrome , cytokine , antibody , outbreak , interleukin 1 receptor antagonist , receptor , virology , immune system , receptor antagonist , immunotherapy , infectious disease (medical specialty) , disease , chimeric antigen receptor , antagonist
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom